Table 1.

Patient characteristics

IDAge (sex)Cancer typeDose level, cfuECOG PSPrior therapiesMesothelin IHCaNo. of doses
ANZ-100
 01-00257 (F)Pancreatic10602NA1
 02-00353 (M)Colorectal10602NA1
 02-00669 (M)Colorectal10615NA1
 01-00562 (M)Pancreatic3 × 10702NA1
 02-05466 (M)Melanoma3 × 10704NA1
 02-05871 (M)Colorectal3 × 10704NA1
 01-00849 (F)Colorectal3 × 10804NA1
 02-06257 (M)Colorectal3 × 10805NA1
 02-06460 (M)Colorectal3 × 10805NA1
CRS-207
 001-00165 (M)Pancreatic1080550%, 2–3+4
 001-00261 (F)Pancreatic10804NE4
 003-00165 (F)Mesothelioma1080225%, 1–2+4
 002-00164 (F)Ovarian10818NE2
 002-00260 (M)Mesothelioma10811NE2
 004-00155 (M)Mesothelioma10804NE3
 005-00256 (F)NSCLC3 × 1080470%, 2–3+1
 001-00468 (F)Pancreatic3 × 10801NE3
 001-00560 (M)Pancreatic3 × 1081175%, 2–3+2
 005-00379 (F)Pancreatic3 × 1080080%, 2–3+2
 004-00259 (M)Pancreatic10914NE4
 005-00156 (F)NSCLC1090550%, 2+4
 001-00361 (M)Pancreatic10902NE4
 002-00372 (F)NSCLC10915100%, 3+4
 002-00475 (M)Mesothelioma10914NE2
 003-00252 (F)Ovarian109110NE4
 003-00340 (M)Mesothelioma101012NE1

Abbreviations: ECOG, Eastern Cooperative Oncology Group; NA, not applicable; NE, not evaluable; PS, performance status.

  • aMesothelin IHC: the percentage of tumor cells showing membranous staining were evaluated for intensity (0, no staining; 1+, weak staining; 2+, moderate staining; 3+, strong staining).